Captrust Financial Advisors Purchases 1,647 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Captrust Financial Advisors lifted its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 19.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 10,170 shares of the medical device company’s stock after purchasing an additional 1,647 shares during the period. Captrust Financial Advisors’ holdings in Tandem Diabetes Care were worth $431,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in TNDM. Brooklyn Investment Group bought a new stake in shares of Tandem Diabetes Care in the 3rd quarter worth approximately $28,000. Assetmark Inc. bought a new stake in Tandem Diabetes Care in the third quarter valued at $29,000. ORG Wealth Partners LLC bought a new stake in Tandem Diabetes Care in the third quarter valued at $30,000. ORG Partners LLC bought a new stake in Tandem Diabetes Care in the second quarter valued at $31,000. Finally, Waldron Private Wealth LLC bought a new stake in shares of Tandem Diabetes Care during the 3rd quarter valued at about $50,000.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Barclays lifted their price objective on Tandem Diabetes Care from $58.00 to $60.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. Sanford C. Bernstein began coverage on shares of Tandem Diabetes Care in a report on Wednesday, November 6th. They set an “outperform” rating and a $42.00 target price on the stock. Robert W. Baird dropped their price objective on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating on the stock in a research note on Thursday, November 7th. Citigroup dropped their price objective on shares of Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Royal Bank of Canada assumed coverage on Tandem Diabetes Care in a research report on Wednesday, October 2nd. They issued an “outperform” rating and a $65.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $53.81.

Tandem Diabetes Care Trading Down 0.6 %

Tandem Diabetes Care stock opened at $34.31 on Friday. The stock has a market cap of $2.25 billion, a P/E ratio of -17.78 and a beta of 1.33. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. Tandem Diabetes Care, Inc. has a 1 year low of $21.85 and a 1 year high of $53.69. The firm’s 50 day moving average price is $33.00 and its 200-day moving average price is $39.82.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.08. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company had revenue of $243.97 million for the quarter, compared to the consensus estimate of $224.14 million. During the same period in the previous year, the firm posted ($0.38) EPS. Tandem Diabetes Care’s revenue for the quarter was up 31.4% compared to the same quarter last year. On average, equities analysts predict that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Kim D. Blickenstaff sold 10,000 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the sale, the director now directly owns 195,190 shares in the company, valued at $5,855,700. The trade was a 4.87 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 2.20% of the company’s stock.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.